ANI Pharmaceuticals Expands Access to Nitazoxanide with New Generic Launch

ANI Pharmaceuticals (Nasdaq: ANIP) has announced the launch of its generic Nitazoxanide Tablets, 500 mg, providing a more accessible alternative to Alinia®. This launch reinforces ANI’s commitment to delivering high-quality, affordable medications in niche markets with limited competition. “The introduction of Nitazoxanide aligns with our mission of ‘Serving Patients, Improving Lives,’ ensuring more people have access to essential treatments,” said ANI President and CEO Nikhil Lalwani.

Partnering with Biophore, ANI brings a vital treatment option to market at a time when affordability remains a key concern for many patients. “We are proud to collaborate on this launch and support ANI’s mission to make critical medications more accessible,” said Dr. Jagadeesh Rangisetty, CEO of Biophore. According to IQVIA data, U.S. annual sales for Nitazoxanide Tablets reached $36.1 million as of December 2024, highlighting the growing demand for cost-effective therapeutic alternatives.